What top creators are saying about Amgen Inc.(AMGN)

Its acquisition of Decode was cited as an example of biological data contributing to drug development. The broader biotech discussion was positive on long-term potential but cautious about timelines, financing, and clinical risk.

After jokingly calling it “Scamgen,” the speaker said Amgen was a good company, but gave no valuation or specific recommendation.

Revenue and EPS beat expectations and grew year over year, but the initial share-price response was muted. The discussion provided limited further outlook or risk details.

Mentioned as an example of a company whose Neulasta line-extension efforts, in the speaker's view, failed to achieve their intended result; no specific investment view on Amgen was offered.

Named among companies employing lobbyists who previously worked in federal government; no specific count, policy issue, or financial impact is provided.

Amgen was held in 37 of 38 quarters by a most-connected strategy, which returned 179%, below the equal-weighted S&P 500's 192%. The text suggests static roster size may be less informative than changes in connections.

Included as a large-cap pharmaceutical name to examine, without a company-specific investment thesis.

Mentioned as an example of a healthcare company involved in changes associated with AI; no company-specific investment case was provided.

Used as a technical reference for a Stage 2 breakout pattern, suggesting a significant upward price maturation phase.

PCSK9 inhibitors are highlighted as a superior pharmaceutical alternative to statins for lowering LDL and slowing plaque progression.

Bullish on execution for Repatha and Crystexa, but skeptical of MariTide's safety and efficacy profile compared to competitors.

The company's breakthrough drug, Repatha, was highlighted with a powerful personal testimonial from Ray Kurzweil, positioning Amgen as a direct way to invest in successful treatments for major age-related conditions.

The company's drug, Repatha, was cited as a prime example of current progress in biotechnology, highlighting the bullish outlook for the sector driven by AI-accelerated drug discovery.

Poised to benefit from a cheaper and faster path to market for biosimilars due to reduced FDA red tape, which could be a significant growth driver.

Highlighted as a prime example of a company leveraging AI, using OpenAI's most advanced models to speed up drug development. This is considered a positive indicator for the company's long-term innovation pipeline.

Praised for its effective and aggressive legal strategy to defend its patents, which is a significant bullish factor for preserving high-margin sales from generic competition.

The speaker believes the market overreacted to 'good' data for its obesity drug, Meritide, and sees a contrarian buy opportunity. He personally bought some on the dip and notes a breakout above $275 could be a buy signal.